Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey

Claudia Pansieri, Chiara Pandolfini, Valery Elie, Mark A Turner, Sailesh Kotecha, Evelyne Jacqz-Aigrain, Maurizio Bonati, Claudia Pansieri, Chiara Pandolfini, Valery Elie, Mark A Turner, Sailesh Kotecha, Evelyne Jacqz-Aigrain, Maurizio Bonati

Abstract

A survey was set up to gauge the opinions of neonatologists on the role of Ureaplasma in bronchopulmonary dysplasia (BPD) development, the use of azithromycin for BPD prevention, and the factors influencing azithromycin use in European neonatal intensive care units (NICUs). 167 NICUs participated in the survey, representing 28 European countries. For respondents, the two major perceived risk factors for BPD were prematurity of <28 weeks and high oxygen requirements. Only 38% of NICUs had a protocol for BPD prevention and 47% routinely tested for Ureaplasma. In cases of infection, macrolides were the first choice. Most (78%) NICUs were interested in participating in a trial evaluating azithromycin safety and efficacy in reducing BPD rates. Opinions and clinical practice varied between European neonatal units, and differences in Ureaplasma treatment and prevention of BPD highlight the need for further azithromycin evaluation and for improved therapeutic knowledge in preterms.

Conflict of interest statement

The authors declare no competing financial interests.

References

    1. Baraldi E. & Filippone M. Chronic lung disease after premature birth. N. Engl. J. Med. 357, 1946–1955 (2007).
    1. Walsh M. C. et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 114, 1305–1311(2004).
    1. Lall A., Prendergast M. & Greenough A. Risk factors for the development of bronchopulmonary dysplasia: the role of antenatal infection and inflammation. Expert Rev. Respir. Med. 1, 247–254 (2007).
    1. Philip A. G. Chronic lung disease of prematurity: a short history. Semin. Fetal Neonatal Med. 14, 333–338 (2009).
    1. Lahra M. M., Beeby P. J. & Jeffery H. E. Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study. Pediatrics. 123, 1314–1319 (2009).
    1. Redline R. W., Wilson-Costello D. & Hack M. Placental and other perinatal risk factors for chronic lung disease in very low birth weight infants. Pediatr. Res. 52, 713–719 (2002).
    1. Bhandari V. & Gruen J. R. The genetics of bronchopulmonary dysplasia. Semin. Perinatol. 30, 185–191 (2006).
    1. Hadchouel A. et al. Identification of SPOCK2 as a susceptibility gene for bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 184, 1164–1170 (2011).
    1. Beeton M. L. et al. Role of pulmonary infection in the development of chronic lung disease of prematurity. Eur. Respir. J. 37, 1424–1430 (2011).
    1. Cassell G. H. et al. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet. 2, 240–245 (1988).
    1. Viscardi R. M. & Hasday J. D. Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence. Pediatr. Res. 65, 84R–90R (2009).
    1. Waites K. B., Katz B. & Schelonka R. L. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin. Microbiol. Rev. 18, 757–789 (2005).
    1. Abele-Horn M., Wolff C., Dressel P., Pfaff F. & Zimmermann A. Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease. J. Clin. Microbiol. 35, 1199–1202 (1997).
    1. Jobe A. H. & Ikegami M. Antenatal infection/inflammation and postnatal lung maturation and injury. Respir. Res. 2, 27–32 (2001).
    1. Turner M. A., Jacqz-Aigrain E. & Kotecha S. Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development. Arch. Dis. Child. 97, 573–577 (2012).
    1. Gortner L. et al. Rates of bronchopulmonary dysplasia in very preterm neonates in Europe: results from the MOSAIC cohort. Neonatology. 99, 112–117 (2011).
    1. Cassell G. H., Waites K. B., Watson H. L., Crouse D. T. & Harasawa R. Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns. Clin. Microbiol. Rev. 6, 69–87 (1993).
    1. Sanchez P. J. Perinatal transmission of Ureaplasma urealyticum: current concepts based on review of the literature. Clin. Infect. Dis. 17 Suppl 1 S107–S111 (1993).
    1. Ballard H. O. et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial. Pediatr. Pulmonol. 46, 111–118 (2011).
    1. Maxwell N. C., Nuttall D. & Kotecha S. Does Ureaplasma spp. cause chronic lung disease of prematurity: ask the audience? Early Hum. Dev. 85, 291–296 (2009).
    1. Payne M. S. et al. Molecular microbiological characterization of preterm neonates at risk of bronchopulmonary dysplasia. Pediatr. Res. 67, 412–418 (2010).
    1. Miralles R. et al. Relationship between antenatal inflammation and antenatal infection identified by detection of microbial genes by polymerase chain reaction. Pediatr. Res. 57, 570–577 (2005).
    1. Kotecha S., Chan B., Azam N., Silverman M. & Shaw R. J. Increase in interleukin-8 and soluble intercellular adhesion molecule-1 in bronchoalveolar lavage fluid from premature infants who develop chronic lung disease. Arch. Dis. Child. Fetal Neonatal Ed. 72, F90–F96 (1995).
    1. Ozdemir R. et al. Clarithromycin in preventing bronchopulmonary dysplasia in Ureaplasma urealyticum-positive preterm infants. Pediatrics. 128, e1496–e1501 (2011).
    1. Lyon A. J. et al. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 78, F10–F14 (1998).
    1. Jonsson B., Rylander M. & Faxelius G. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr. 87, 1079–1084 (1998).
    1. Baier R. J., Loggins J. & Kruger T. E. Failure of erythromycin to eliminate airway colonization with ureaplasma urealyticum in very low birth weight infants. BMC Pediatr. 3, 10 (2003).
    1. Gharehbaghi M. M., Peirovifar A., Ghojazadeh M. & Mahallei M. Efficacy of azithromycin for prevention of bronchopulmonary dysplasia (BPD). Turk J. Med. Sci. 42, 1070–1075 (2012).
    1. Samra Z., Rosenberg S. & Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J. Chemother. 23, 77–9 (2011).
    1. Walls S. A. et al. Antibiotic prophylaxis improves Ureaplasma-associated lung disease in suckling mice. Pediatr. Res. 66, 197–202 (2009).
    1. Mabanta C. G., Pryhuber G. S., Weinberg G. A. & Phelps D. L. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst. Rev. CD003744 (2003).
    1. Ballard H. O., Anstead M. I. & Shook L. A. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir. Res. 8, 41 (2007).
    1. Hassan H. E. et al. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia. J. Clin. Pharmacol. 51, 1264–75 (2011).
    1. Viscardi R. M. et al. Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose. Antimicrob. Agents Chemother. 57, 2127–33 (2013).
    1. Ray W. A., Murray K. T., Hall K., Arbogast P. G. & Stein C. M. Azithromycin and the risk of cardiovascular death. N. Engl. J. Med. 366, 1881–1890 (2012).
    1. Bancalari E. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am. J. Perinatol. 18, 1–9 (2001).
    1. Schelonka R. L. & Waites K. B. Ureaplasma infection and neonatal lung disease. Semin. Perinatol. 31, 2–9 (2007).
    1. Kaguelidou F. et al. European survey on the use of prophylactic fluconazole in neonatal intensive care units. Eur. J. Pediatr. 171, 439–445 (2012).
    1. Stark A. R. Levels of neonatal care. Pediatrics. 114, 1341–1347 (2004).

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit